Determination of Remifentanil's ED50 for Rapid Sequence Intubation Avoiding Bradycardia and Hypotension in Adults

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03065309

Enrollment

Registered

2017-02-27

Start date

2017-02-25

Completion date

2017-03-01

Last updated

2017-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bradycardia, Hypotension

Brief summary

This study will find the median effective dose of remifentanil for rapid sequence intubation which avoids bradycardia and hypotension

Detailed description

Remifentanil is becoming popular for rapid sequence intubation because it has a fast onset and ultra-short half-life. Remifentanil a potent opioid associated to bradycardia and hypotension at high doses.

Interventions

DRUGRemifentanil

bolus dose

Study design

Intervention model

SEQUENTIAL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Masking description

Participant will receive propofol before induction

Intervention model description

Adaptative clinical trial, Dixon's Up-And-Down Method

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Indication of anesthesia induction

Exclusion criteria

* Protocol violation * Monitoring problems

Design outcomes

Primary

Measure	Time frame	Description
hemodynamic stability during rapid sequence intubation	from anesthesia induction up to 5 minutes	no bradycardia and no hypotension

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026